A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Completed · Phase 1 · NCT06578585
Conditions: Migraine
At a glance
- Research payments reported, 2025
- $842,567
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 43
About the trial
- Sponsor
- H. Lundbeck A/S
- Tested
- Ubrogepant (drug), Lu AG09222 (drug), Placebo (drug)
- Dates
- Started 2024-09-13; completion 2025-07-11
- Results posted
- Not yet
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.
From ClinicalTrials.gov, last updated 2025-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
H. Lundbeck A S reported $842,567 in research payments for this study in 2025 (59 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Matthews W. Gwynn, M.D. Neurology · Atlanta, GA
- Felipe P. Suplicy, M.D. Psychiatry · Rome, GA
- John D. Hudson, M.D. Sleep Medicine · Austin, TX
- Joe E. Pouzar JR., M.D Family Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Elevate Clinical Research Inc $303,107
- Clinical Neuroscience Solutions Inc $211,289
- Futuresearch Trials of Neurology LLC $171,939
- Neurotrials Research $141,949
- Neurotrials Research Inc $14,283
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.